

AMENDMENTS TO THE CLAIMS

Listing of the claims

1.-14. (Cancelled)

15. (Withdrawn, Currently amended) The use of a binding molecule according to any one of claims 19, 20, and 21, 22, 23 and 24 as a pharmaceutical.

16. (Withdrawn, Currently amended) The use of a binding molecule according to any one of claims 19, 20, and 21, 22, 23 and 24 in the treatment of nerve repair.

17. (Currently amended) A **pharmaceutical** composition comprising a binding molecule according to any one of claims 19, 20, and 21, 22, 23 and 24 in association with at least one **pharmaceutically-acceptable** carrier or diluent.

18. (Withdrawn, Currently amended) A method of treatment of diseases associated with nerve repair comprising administering to a subject in need of such treatment an effective amount of a binding molecule according to any one of claims 19, 20, and 21, 22, 23 and 24.

19. (Currently amended) An isolated human Nogo_A623-640 binding molecule which comprises a heavy chain variable domain or fragment thereof, and wherein said heavy chain variable domain or fragment thereof comprises comprising in sequential order sequence SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10 SEQ ID NO:10.

20. (Currently amended) An isolated human Nogo_A623-640 binding molecule which comprises a light chain variable domain or fragment thereof, and wherein said light

chain variable domain or fragment thereof comprises comprising in sequential order sequencee SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13SEQ ID NO:13.

21. (Currently amended) An isolated human Nogo_A623-640 binding molecule which comprises a heavy chain variable domain or fragment thereof, and wherein said heavy chain variable domain or fragment thereof comprises SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10SEQ ID NO:10; and a light chain variable domain or fragment, and wherein said light chain variable domain or fragment thereof comprises comprising in sequential order sequencee SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13SEQ ID NO:13.

22-24. (Cancelled)